Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Rating of “Hold” from Brokerages

Shares of Arvinas, Inc. (NASDAQ:ARVN) have been assigned an average recommendation of “Hold” from the thirteen analysts that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $15.4167.

Several equities analysts have recently weighed in on ARVN shares. Truist Financial set a $10.00 price target on Arvinas in a report on Wednesday, March 18th. Piper Sandler reissued an “overweight” rating and set a $20.00 price target (up from $16.00) on shares of Arvinas in a report on Wednesday, February 25th. Barclays raised their target price on Arvinas from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. Wedbush raised their target price on Arvinas from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Tuesday, February 24th. Finally, Wall Street Zen cut Arvinas from a “hold” rating to a “sell” rating in a report on Monday, March 2nd.

Insider Buying and Selling

In related news, CEO Randy Teel sold 9,657 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $9.94, for a total value of $95,990.58. Following the transaction, the chief executive officer directly owned 287,218 shares of the company’s stock, valued at approximately $2,854,946.92. This trade represents a 3.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Andrew Saik sold 11,139 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $9.94, for a total value of $110,721.66. Following the completion of the transaction, the chief financial officer directly owned 193,128 shares in the company, valued at approximately $1,919,692.32. This represents a 5.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 42,467 shares of company stock valued at $427,598. 7.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Arvinas

Institutional investors have recently bought and sold shares of the stock. Hussman Strategic Advisors Inc. purchased a new stake in Arvinas in the 4th quarter worth $1,245,000. JPMorgan Chase & Co. increased its stake in Arvinas by 475.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 214,779 shares of the company’s stock worth $1,830,000 after buying an additional 177,460 shares in the last quarter. Brummer Multi Strategy AB purchased a new stake in Arvinas in the 4th quarter worth $1,973,000. BML Capital Management LLC purchased a new stake in Arvinas in the 3rd quarter worth $426,000. Finally, Arbiter Partners Capital Management LLC purchased a new stake in Arvinas in the 3rd quarter worth $3,858,000. 95.19% of the stock is owned by institutional investors.

Arvinas Price Performance

NASDAQ ARVN opened at $7.21 on Friday. The business’s fifty day moving average price is $9.78 and its 200-day moving average price is $11.44. The stock has a market capitalization of $465.19 million, a price-to-earnings ratio of -2.17 and a beta of 1.74. Arvinas has a 1-year low of $6.05 and a 1-year high of $14.51.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.05. The firm had revenue of $15.60 million for the quarter, compared to analysts’ expectations of $16.61 million. Arvinas had a negative return on equity of 44.38% and a negative net margin of 247.54%.The company’s revenue was down 91.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.14 EPS. Equities research analysts anticipate that Arvinas will post -2.83 EPS for the current year.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.